Vanguard Global Advisers
PRAX icon

Vanguard Global Advisers’s Praxis Precision Medicines PRAX Stock Holding History

Vanguard Global Advisers’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Buy
12,052
+717
+6% +$227K ﹤0.01% 881
2026
Q1 		$3.65M Buy
+11,335
New +$3.51M ﹤0.01% 879

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Global Advisers's PRAX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Praxis Precision Medicines (PRAX) stake by 6.3% in Q2 2026, buying an estimated $227K and bringing the position to 12,052 shares worth $4.03M. The position accounts for ﹤0.01% of the portfolio, ranked #881.

Vanguard Global Advisers first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 304 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Vanguard Global Advisers held 12,052 shares of Praxis Precision Medicines worth $4.03M as of Q2 2026.
  • Vanguard Global Advisers bought 717 Praxis Precision Medicines shares in Q2 2026, an estimated $227K.
  • Praxis Precision Medicines made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #881 holding.
  • Vanguard Global Advisers first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 304 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.